clinic
spectrum
lung
injuri
secondari
hemotherapi
develop
lung
injuri
transfus
blood
product
occur
clinic
spectrum
therefor
proper
recognit
lung
injuri
must
consid
possibl
scenario
transfusionrel
acut
lung
injuri
trali
classic
recogn
form
fulmin
develop
new
lung
injuri
patient
receiv
receiv
bloodproduct
transfus
often
sever
respiratori
failur
develop
frothi
pulmonari
edema
fluid
suction
endotrach
tube
catastroph
fulmin
form
trali
easili
diagnos
health
care
provid
like
patholog
process
howev
trali
extend
spectrum
mild
sever
milder
form
trali
go
unrecogn
even
highli
train
experienc
health
care
provid
exampl
trali
stabl
patient
gener
medic
ward
receiv
pack
red
blood
cell
prbc
anemia
develop
mild
decreas
oxygen
satur
may
go
unrecogn
caus
oxygen
desatur
may
blindli
assign
volum
overload
recent
retrospect
studi
track
recipi
blood
product
donor
implic
case
trali
exemplifi
point
highli
motiv
donor
link
case
trali
period
mani
case
associ
mild
symptom
mild
oxygen
desatur
case
initi
recogn
trali
report
blood
bank
potenti
advers
event
essenti
health
care
provid
maintain
high
degre
vigil
advers
reaction
blood
product
investig
thoroughli
oxygen
desatur
tempor
relat
bloodproduct
transfus
anoth
import
categori
potenti
lung
injuri
relat
bloodproduct
transfus
worsen
preexist
acut
lung
injuri
ali
subsequ
hemotherapi
often
difficult
make
diagnosi
trali
critic
ill
patient
exist
aliacut
respiratori
distress
syndrom
ard
howev
sudden
worsen
oxygen
pulmonari
complianc
patient
receiv
past
hour
receiv
bloodproduct
transfus
absenc
sign
volum
overload
probabl
diagnosi
trali
made
studi
medic
literatur
support
contribut
bloodproduct
transfus
worsen
preexist
aliard
use
largest
prospect
studi
incid
ali
pediatr
popul
church
colleagu
retrospect
assess
role
bloodproduct
transfus
clinic
outcom
patient
popul
investig
discov
transfus
fresh
frozen
plasma
ffp
independ
risk
factor
mortal
pediatr
ali
patient
day
adult
prospect
investig
risk
factor
incid
outcom
aliard
singl
center
gong
colleagu
report
prbc
transfus
independ
associ
initi
develop
aliard
independ
risk
factor
mortal
aliard
dosedepend
respons
potenti
lesson
also
learn
semin
transfus
requir
critic
care
tricc
trial
canadian
care
trial
group
random
control
equival
trial
compar
restrict
liber
transfus
threshold
patient
transfus
hemoglobin
trigger
less
gdl
least
good
outcom
patient
liber
transfus
arm
analysi
icu
complic
develop
two
group
patient
patient
restrict
transfus
group
versu
patient
liber
transfus
group
develop
ard
icu
stay
p
unfortun
determin
proport
patient
ard
develop
overt
trali
howev
provoc
consid
proport
ard
may
prevent
adher
lower
transfus
threshold
potenti
benefit
could
result
reduct
aliard
directli
caus
transfus
blood
product
aliard
result
combin
blood
transfus
caus
twohit
model
tricc
trial
decreas
infecti
complic
eg
pneumonia
sepsi
seem
benefit
restrict
transfus
group
thu
decreas
incid
aliard
probabl
attribut
decreas
transfusionrel
immunomodul
one
notabl
point
consid
regard
tricc
trial
statist
signific
decreas
pulmonari
edema
restrict
transfus
group
pulmonari
edema
list
cardiac
complic
although
unclear
rigor
noncardiogen
pulmonari
edema
exclud
decreas
pulmonari
edema
could
potenti
compris
transfusionassoci
circulatori
overload
trali
term
transfusionrel
acut
lung
injuri
first
coin
popovski
moor
variabl
defin
ensu
year
recent
field
aid
significantli
consensu
definit
develop
panel
investig
conven
nation
heart
lung
blood
institut
nhlbi
simpli
put
trali
remain
clinic
diagnosi
similar
clinic
definit
use
ali
ard
fact
patient
meet
clinic
criteria
aliard
receiv
bloodproduct
transfus
previou
hour
absenc
anoth
credibl
risk
factor
ard
clinic
diagnosi
trali
made
blood
bank
laboratori
workup
trali
import
compon
possibl
prevent
futur
trali
implic
blood
donor
requir
make
diagnosi
trali
use
window
implic
bloodproduct
transfus
trali
arbitrari
design
multitud
case
report
medic
literatur
confirm
close
tempor
associ
transfus
blood
product
fact
common
trali
develop
first
minut
transfus
experiment
evid
anim
model
support
tempor
associ
least
four
differ
anim
model
trali
use
antineutrophil
antibodi
antimajor
histocompat
class
mhc
antibodi
plasma
lipid
fraction
day
prbc
day
platelet
lung
injuri
develop
within
hour
challeng
experiment
agent
fact
mhc
antibodi
model
lung
injuri
develop
within
hour
often
within
minut
speed
lung
injuri
develop
given
patient
probabl
complex
interplay
host
suscept
dose
titer
injuri
blood
product
clinic
diagnosi
trali
potenti
complic
exist
major
risk
factor
aliard
clinic
risk
factor
often
present
critic
ill
patient
receiv
hemotherapi
consensu
definit
trali
address
point
assign
definit
diagnosi
trali
aliard
risk
factor
present
probabl
diagnosi
trali
major
risk
factor
present
clinic
cours
probabl
trali
patient
follow
time
credibl
relationship
risk
factor
aliard
assess
hemotherapi
remain
credibl
risk
factor
aliard
diagnosi
trali
made
issu
massiv
transfus
risk
factor
aliard
potenti
sourc
confus
assign
diagnosi
trali
massiv
transfus
defin
replac
transfus
patient
blood
volum
hour
massiv
transfus
implic
major
risk
factor
aliard
multipl
studi
probabl
fourth
common
caus
aliard
account
approxim
case
even
experiment
model
massiv
blood
transfus
entir
clear
lung
injuri
produc
insult
mani
patient
major
involv
trauma
consider
includ
ischemiareperfus
lung
injuri
shock
potenti
compon
direct
thorac
trauma
older
investig
use
anim
model
shock
lung
disprov
microaggreg
particul
theori
lung
injuri
transfus
focus
attent
plasma
fraction
blood
product
possibl
develop
aliard
massiv
blood
transfus
function
cumul
risk
trali
individu
blood
product
supposit
may
explain
mani
case
receiv
multipl
blood
product
place
patient
higher
risk
receiv
incompat
product
contain
either
match
antibodi
prime
activ
bioactiv
lipid
one
consid
twohit
model
trali
underli
medic
condit
critic
ill
patient
requir
multipl
transfus
also
place
patient
risk
trali
summari
certainti
diagnosi
trali
made
patient
risk
factor
ali
preexist
ali
complic
issu
may
aid
follow
clinic
cours
patient
also
focus
laboratori
investig
implic
blood
product
consist
incid
trali
report
medic
literatur
blood
product
transfus
figur
probabl
signific
underestim
given
evid
underrecognit
underreport
trali
new
consensu
definit
recent
prolifer
case
report
clinic
review
trali
aid
greater
recognit
report
condit
futur
addit
nhlbi
recent
fund
special
center
clinic
orient
research
sccor
grant
univers
california
san
francisco
mayo
clinic
rochest
conduct
prospect
observ
cohort
studi
incid
outcom
trali
two
medic
center
studi
promis
yield
largest
cohort
trali
patient
medic
literatur
provid
reliabl
estim
incid
trali
medic
provid
requir
report
fatal
relat
trali
food
drug
administr
fda
past
year
fda
receiv
report
per
year
fatal
trali
trali
emerg
primari
caus
transfusionassoci
mortal
surpass
infecti
complic
abo
mismatch
unit
kingdom
seriou
hazard
transfus
annual
report
evalu
case
report
trali
event
conclud
case
either
highli
like
probabl
trali
case
possibl
trali
clinic
outcom
patient
trali
differ
consider
outcom
patient
caus
aliard
one
largest
case
seri
trali
literatur
report
clinic
outcom
patient
mayo
clinic
predat
use
low
tidal
volum
ventil
manag
patient
aliard
investig
three
quarter
patient
requir
mechan
ventil
vast
major
patient
rapid
clearanc
hour
pulmonari
edema
two
patient
die
yield
mortal
rapid
clearanc
pulmonari
edema
mortal
differ
consider
allcaus
aliard
estim
mortal
plasmacontain
blood
product
implic
trali
list
includ
whole
blood
prbc
ffp
whole
blood
platelet
apheresi
platelet
less
frequent
associ
intraven
immunoglobulin
cryoprecipit
controversi
exist
concern
blood
product
commonli
implic
trali
two
blood
product
largest
plasma
fraction
ffp
platelet
probabl
top
offend
report
trali
fatal
report
fda
ffp
commonli
implic
product
follow
red
blood
cell
platelet
cryoprecipit
associ
platelet
trali
support
singlecent
investig
report
whole
blood
platelet
caus
trali
case
classic
pathogenesi
trali
explain
passiv
transfus
plasmacontain
blood
product
hla
class
iii
neutrophil
antibodi
recogn
specif
hla
neutrophil
antigen
recipi
numer
case
report
case
seri
document
presenc
antibodi
match
antigen
recipi
anim
model
mhc
antineutrophil
antibodi
produc
acut
lung
injuri
rarer
circumst
role
revers
recipi
antibodi
react
antigen
donor
leukocyt
fda
report
fatal
secondari
trali
antihla
antibodi
frequent
implic
antibodi
follow
antigranulocyt
antihla
ii
antibodi
antimhc
mous
model
reproduc
mani
featur
clinic
trali
lung
injuri
produc
secondari
recognit
endothelialbound
mhc
antibodi
circul
neutrophil
fc
gamma
receptor
anoth
experiment
model
trali
evid
present
mous
monoclon
antineutrophil
antibodi
directli
activ
human
neutrophil
lead
lung
injuri
common
antibodi
model
howev
central
role
neutrophil
produc
diseas
either
direct
antibodi
activ
indirectli
fc
gamma
receptor
activ
investig
shown
monocyt
may
import
trali
pathogenesi
although
antibodi
theori
trali
support
clinic
experiment
evid
solid
clinic
data
anim
model
also
implic
biolog
activ
lipid
accumul
older
cellular
blood
product
biolog
activ
lipid
thought
breakdown
product
cellular
membran
store
blood
product
prime
activ
neutrophil
vitro
cellular
blood
product
prbc
platelet
shown
accumul
lipid
time
plasma
lipid
fraction
older
blood
product
use
produc
pulmonari
edema
isol
perfus
rat
lung
model
older
blood
product
implic
trali
case
recent
red
blood
cell
storag
time
associ
develop
new
aliard
phenomenon
adequ
explain
inconsist
develop
lung
injuri
even
recipi
transfus
match
hla
neutrophil
antibodi
exampl
retrospect
studi
trali
involv
antibodi
neutrophil
antigen
expect
present
recipi
produc
trali
minor
patient
transfus
antibodi
lack
consist
relationship
antibodyantigen
match
trali
explain
host
suscept
specif
twohit
model
trali
hypothesi
state
recipi
must
underli
medic
condit
contribut
immun
prime
transfus
hla
neutrophil
antibodi
biolog
activ
lipid
trali
produc
evid
support
hypothesi
includ
frequent
occurr
trali
icu
oper
room
epidemiolog
associ
cardiopulmonari
bypass
hematolog
malign
addit
biolog
activ
lipid
model
involv
necessari
system
endotoxinprim
step
produc
ali
host
suscept
factor
genet
polymorph
also
may
contribut
factor
patient
develop
trali
often
develop
dyspnea
tachypnea
hypoxia
hypotens
hypertens
report
patient
trali
hyperand
hypothermia
mechan
ventil
patient
time
endotrach
intub
frothi
pulmonari
edema
fluid
sometim
elabor
fulmin
trali
case
criteria
use
clinician
research
diagnos
caus
aliard
use
make
diagnosi
trali
chest
imag
reveal
bilater
pulmonari
opac
pattern
consist
noncardiogen
pulmonari
edema
fig
adjunct
test
aid
trali
diagnosi
includ
echocardiographi
serial
white
blood
cell
count
protein
analysi
undilut
pulmonari
edema
fluid
echocardiographi
aid
workup
help
exclud
volum
overload
cardiogen
dysfunct
often
patient
fulmin
trali
evid
low
cardiac
fill
pressur
measur
brain
natriuret
peptid
may
also
adjunct
test
help
sever
case
report
leukopenia
neutropenia
tempor
associ
onset
pulmonari
edema
trali
laboratori
find
often
dynam
leukocyt
count
recov
hour
initi
trali
even
one
case
report
leukopenia
herald
onset
trali
mous
mhc
antibodi
model
trali
also
document
phenomenon
speak
associ
leukopenia
diseas
pathogenesi
caus
ali
ard
eg
pneumonia
sepsi
also
might
produc
leukopenia
find
specif
trali
thrombocytopenia
decreas
complement
report
also
much
less
frequent
final
present
measur
protein
concentr
undilut
pulmonari
edema
fluid
match
plasma
sampl
help
document
permeabl
pulmonari
edema
thu
help
exclud
transfusionassoci
circulatori
overload
cardiogen
pulmonari
edema
uniqu
specif
treatment
trali
proper
recognit
syndrom
lead
provis
support
care
given
patient
aliard
addit
correctli
identifi
trali
allow
one
avoid
potenti
injuri
intervent
diuret
patient
often
volum
deplet
paradox
patient
sometim
sever
pulmonari
edema
may
requir
intraven
fluid
support
blood
pressur
colloid
vasopressor
may
requir
instanc
corticosteroid
role
treatment
trali
patient
import
consid
patient
trali
improv
fairli
rapidli
overal
mortal
low
thu
patienc
avoid
unnecessari
bloodproduct
transfus
patient
well
trali
best
prevent
avoid
unnecessari
bloodproduct
transfus
use
evidencebas
transfus
trigger
use
erythropoietin
recombin
factor
vii
may
help
reduc
transfus
requir
select
popul
expert
agre
blood
donor
implic
trali
case
donor
donor
exist
blood
product
remov
perman
donor
pool
given
incid
hla
sensit
multipar
femal
associ
trali
ffp
transfus
unit
kingdom
exclud
women
donat
ffp
direct
donat
instead
plasmapoor
blood
product
addit
platelet
pool
suspend
male
plasma
much
possibl
ampl
time
determin
benefit
regulatori
action
incid
trali
howev
number
highli
like
probabl
trali
case
decreas
next
report
year
leukoreduct
prbc
almost
univers
blood
bank
procedur
unlik
significantli
reduc
incid
trali
recipi
antibodi
recognit
antigen
donor
leukocyt
rare
mechan
trali
clinic
import
epidemiolog
sever
acut
respiratori
syndrom
sever
acut
respiratori
syndrom
sar
burst
intern
scene
caus
much
concern
rapid
global
dissemin
fear
pandem
late
peopl
develop
probabl
sar
mani
differ
countri
across
five
contin
predomin
case
china
hong
kong
viet
nam
taiwan
singapor
canada
approxim
one
four
patient
sar
becom
critic
ill
ali
occur
patient
patient
fact
ali
common
organsystem
dysfunct
sar
patient
patient
becom
critic
ill
sar
approxim
die
mortal
rate
increas
elderli
much
learn
epidemiolog
sar
sinc
emerg
guangdong
provinc
china
remark
collabor
multipl
laboratori
differ
countri
novel
coronaviru
identifi
caus
agent
sar
month
initi
report
sar
outbreak
similar
coronaviru
also
isol
wild
anim
eg
himalayan
palm
civet
raccoon
dog
sold
wet
market
guangdong
provinc
support
zoonot
origin
novel
viru
incub
period
sar
seem
rang
day
although
longer
incub
time
document
unlik
influenza
transmiss
peak
soon
onset
clinic
symptom
sar
transmit
effici
day
ill
primari
rout
transmiss
contact
direct
indirect
respiratori
droplet
fomit
fecalor
spread
also
may
play
role
given
presenc
sar
coronaviru
stool
specimen
presenc
wateri
diarrhea
mani
affect
patient
spread
sar
seem
involv
socal
superspread
disproportion
infect
mani
person
also
promin
involv
transmiss
healthcar
set
clinic
sar
work
group
compris
expert
canada
unit
state
determin
patient
admit
icu
respiratori
failur
secondari
sar
met
establish
clinic
definit
aliard
lung
patholog
obtain
sar
nonsurvivor
reveal
pattern
diseas
indistinguish
caus
aliard
name
diffus
alveolar
damag
much
learn
potenti
cellular
molecular
mechan
lung
injuri
secondari
sar
coronaviru
infect
exampl
tropism
sar
coronaviru
lung
gastrointestin
tract
explain
epitheli
distribut
cellular
receptor
found
surfac
alveolar
type
ii
epitheli
cell
also
small
bowel
enterocyt
therefor
sever
pulmonari
damag
observ
sar
explain
viralalveolar
epitheli
cell
interact
diagnosi
manag
prevent
sever
acut
respiratori
syndrom
sar
present
clinic
nonspecif
viral
syndrom
fever
myalgia
chill
fatigu
cough
upper
respiratori
symptom
eg
rhinorrhea
sore
throat
often
absent
wateri
diarrhea
present
patient
sever
affect
patient
develop
short
breath
tachypnea
tachycardia
routin
laboratori
investig
often
reveal
lymphopenia
thrombocytopenia
elev
transaminas
chest
imag
nonspecif
highresolut
ct
abnorm
nearli
patient
show
groundglass
attenu
focal
consolid
case
pneumomediastinum
diagnosi
sar
reli
consider
key
epidemiolog
data
patient
viral
syndrom
idiopath
respiratori
failur
clinic
syndrom
routin
laboratori
test
chest
imag
nonspecif
diagnosi
reli
detect
sar
coronaviru
clinic
specimen
realtim
polymeras
chain
reaction
pcr
use
test
sampl
multipl
potenti
site
includ
upper
lower
respiratori
tract
stool
urin
plasma
viru
concentr
lower
respiratori
tract
present
low
quantiti
earli
diseas
cours
thu
neg
result
earli
clinic
cours
especi
upper
respiratori
specimen
interpret
caution
standard
diagnost
test
sar
seroconvers
test
rare
help
prospect
evidencebas
manag
sar
review
nhlbicent
diseas
control
preventionn
institut
allergi
infect
diseas
clinic
sar
work
group
gener
sar
produc
clinic
syndrom
consist
caus
aliard
respiratori
failur
manag
similar
fashion
pressurelimit
low
tidal
volum
strategi
role
antivir
agent
eg
ribavirin
interferona
corticosteroid
controversi
suffer
lack
qualiti
data
anecdot
small
case
seri
support
role
corticosteroid
sever
case
thu
absenc
placebocontrol
trial
steroid
therapi
consid
especi
patient
clinic
deterior
sever
factor
contribut
halt
sar
transmiss
current
disappear
clinic
landscap
involv
world
health
organ
issu
global
health
alert
quarantin
infect
expos
individu
importantli
ban
sale
wildlif
wet
market
guangdong
china
help
stop
spread
potenti
pandem
phase
trial
progress
vaccin
strategi
could
prove
import
sar
reemerg
global
scene
influenza
pandem
mark
emerg
epizoot
strain
influenza
immunolog
memori
human
spanish
influenza
pandem
kill
estim
million
peopl
worldwid
subsequ
pandem
also
kill
mani
thousand
attent
trepid
focus
epizoot
strain
potenti
caus
worldwid
diseas
mortal
viru
first
emerg
chicken
scotland
caus
pandem
among
chicken
southeast
asia
accord
world
health
organ
statist
access
june
human
infect
viru
differ
countri
die
yield
mortal
mani
children
young
adult
almost
person
infect
link
epidemiolog
exposur
sick
bird
small
number
case
exposur
anoth
human
infect
unknown
widespread
lethal
pandem
infect
would
congression
budget
offic
estim
million
peopl
could
infect
unit
state
alon
influenza
subtyp
contain
new
hemagglutinin
human
littl
immun
hemagglutinin
molecul
attach
epitheli
cell
macrophag
lung
interact
cellsurfac
sialic
acid
residu
true
influenza
pandem
develop
avian
viru
spread
effici
human
human
scenario
occur
rare
thu
far
recent
report
might
help
explain
avian
viru
current
ineffici
humantohuman
infect
seem
establish
human
influenza
virus
eg
avian
flu
virus
target
differ
region
human
respiratori
tract
human
flu
virus
preferenti
recogn
sialic
acid
residu
proxim
respiratori
tract
trachea
bronchi
wherea
infect
alveolar
type
ii
cell
macrophag
noncili
cuboid
epithelium
termin
bronchi
differenti
tropism
may
help
explain
clinic
present
aliard
human
infect
perhap
importantli
may
help
explain
transmit
effici
among
human
human
influenza
transmit
easili
proxim
locat
respiratori
tract
wherea
deepli
seat
infect
even
concern
anim
model
infect
viremia
lead
fecal
shed
viru
potenti
fecalor
transmiss
children
young
adult
seem
disproportion
affect
infect
median
age
affect
individu
rang
year
infect
typic
influenzalik
symptom
promin
involv
lower
respiratori
tract
often
accompani
wateri
diarrhea
like
sar
lymphopenia
thrombocytopenia
increas
transaminas
level
often
present
common
radiograph
find
multifoc
consolid
progress
respiratori
failur
occur
major
hospit
individu
within
hour
admiss
diagnosi
reli
consider
appropri
epidemiolog
context
conjunct
revers
transcriptas
pcr
respiratori
sampl
pharyng
sampl
higher
yield
nasal
specimen
current
known
treatment
infect
deviat
substanti
treatment
sever
human
influenza
infect
support
care
patient
aliard
includ
pressurelimit
low
tidal
volum
ventilatori
strategi
antivir
treatment
data
indic
mani
strain
isol
human
resist
adamantan
current
circul
human
influenza
strain
also
recent
becom
highli
resist
strain
isol
human
proven
suscept
neuraminidas
inhibitor
oseltamivir
tamiflu
zanamivir
relenza
although
case
report
isol
resist
oseltamivir
prophylaxi
health
care
worker
postexposur
prophylaxi
would
essenti
element
respons
pandem
provid
adequ
suppli
neuraminidas
inhibitor
avail
potenti
role
corticosteroid
treatment
influenzaassoci
aliard
known
like
primari
focu
annual
influenza
season
prevent
infect
justli
receiv
great
deal
attent
research
throughout
world
race
develop
vaccin
highli
effect
low
side
effect
mass
produc
short
period
time
multipl
strategi
use
produc
immunogen
vaccin
recent
report
use
two
dose
inactiv
subvirion
vaccin
administ
intramuscularli
human
show
highest
dose
vaccin
administ
approxim
half
patient
develop
neutral
antibodi
titer
effect
vaccin
contrast
effect
human
influenza
vaccin
current
use
propos
use
adjuv
may
increas
vaccin
effect
new
hemagglutinin
protein
human
may
poorli
immunogen
group
test
live
attenu
influenza
vaccin
also
adenovirusbas
immun
strategi
elicit
strong
tcell
immun
respons
summari
trali
sar
influenza
recent
describ
caus
aliard
much
learn
mani
question
remain
unansw
biggest
impact
decreas
incid
trali
adher
evidencebas
transfus
guidelin
potenti
regulatori
action
limit
exposur
blood
product
donor
consist
implic
trali
outcom
recent
initi
unit
kingdom
limit
exposur
femal
plasma
follow
close
determin
similar
action
taken
unit
state
threat
sar
temporarili
control
attent
intens
focus
pandem
threat
influenza
potenti
overwhelm
exist
critic
care
resourc
treatment
respiratori
failur
undoubtedli
new
infecti
noninfecti
caus
ali
ard
emerg
futur
mandat
vigil
health
care
provid
provid
challeng
public
health
offici
clinic
basic
scienc
investig
requir
transpar
commun
among
member
today
global
societi
